Search Results - "Marcellin, P"

Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients by Martinot-Peignoux, M., Lapalus, M., Maylin, S., Boyer, N., Castelnau, C., Giuily, N., Pouteau, M., Moucari, R., Asselah, T., Marcellin, P.

“…Summary Quantitative hepatitis B core‐related antigen (qHBcrAg) has been proposed as an additional marker to quantitative HBsAg (qHBsAg), for management of…”
Get full text

Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C by Sasso, M., Tengher-Barna, I., Ziol, M., Miette, V., Fournier, C., Sandrin, L., Poupon, R., Cardoso, A.-C., Marcellin, P., Douvin, C., de Ledinghen, V., Trinchet, J.-C., Beaugrand, M.

“…A novel controlled attenuation parameter (CAP) has been developed for Fibroscan® to assess liver steatosis, simultaneously with liver stiffness measurement…”
Get full text

No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment by Liu, Y., Corsa, A. C., Buti, M., Cathcart, A. L., Flaherty, J. F., Miller, M. D., Kitrinos, K. M., Marcellin, P., Gane, E. J.

“…Summary A major hurdle in the long‐term treatment of chronic hepatitis B (CHB) patients is to maintain viral suppression in the absence of drug resistance. To…”
Get full text

Measurements of Sea Clutter at Low Grazing Angle in Mediterranean Coastal Environment by Fabbro, V., Biegel, G., Forster, J., Poisson, J.-B, Danklmayer, A., Bohler, C., Marcellin, J.-P, Brehm, T., Gallus, M., Castanet, L., Ulland, A., Hurtaud, Y.

“…Results of a coastal measurement campaign called MediterraneAn Rfc and cLutter ENvironmental Experiment (MARLENE) are presented and studied. The campaign was…”
Get full text

STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? by Asselah, T, Rubbia-Brandt, L, Marcellin, P, Negro, F

“…Hepatic steatosis is a common histological feature of chronic hepatitis C. Various factors are associated with hepatic steatosis, including obesity, high…”
Get full text

Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa‐2a combination therapy for chronic hepatitis B by Marcellin, P., Ahn, S. H., Chuang, W.‐L., Hui, A. J., Tabak, F., Mehta, R., Petersen, J., Lee, C.‐M., Ma, X., Caruntu, F. A., Tak, W. Y., Elkhashab, M., Lin, L., Wu, G., Martins, E. B, Charuworn, P., Yee, L. J., Lim, S. G., Foster, G. R., Fung, S., Morano, L., Samuel, D., Agarwal, K., Idilman, R., Strasser, S. I., Buti, M., Gaeta, G. B., Papatheodoridis, G., Flisiak, R., Chan, H. L. Y.

“…Summary Background In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG‐IFN) for 48‐weeks results in higher…”
Get full text

Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C by Asselah, T, Bieche, I, Narguet, S, Sabbagh, A, Laurendeau, I, Ripault, M-P, Boyer, N, Martinot-Peignoux, M, Valla, D, Vidaud, M, Marcellin, P

“…The gold standard treatment of chronic hepatitis C (CHC) is combined pegylated interferon and ribavirin. Considering side effects and treatment cost,…”
Get more information

Shorter durations and lower doses of peginterferon alfa‐2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C by Liaw, Y.‐F., Jia, J.‐D., Chan, H.L.Y., Han, K.H., Tanwandee, T., Chuang, W.L., Tan, D.M., Chen, X.Y., Gane, E., Piratvisuth, T., Chen, L., Xie, Q., Sung, J.J.Y., Wat, C., Bernaards, C., Cui, Y., Marcellin, P.

“…As there is currently a lack of consensus on the most appropriate dose and duration of peginterferon alfa‐2a (PEG‐IFNα‐2a) therapy in hepatitis B e antigen…”
Get full text

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B by Bonino, F, Marcellin, P, Lau, G K K, Hadziyannis, S, Jin, R, Piratvisuth, T, Germanidis, G, Yurdaydin, C, Diago, M, Gurel, S, Lai, M-Y, Brunetto, M R, Farci, P, Popescu, M, McCloud, P

“…In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with…”
Get full text

Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B by Bonino, F, Marcellin, P, Lau, G K K, Hadziyannis, S, Jin, R, Piratvisuth, T, Germanidis, G, Yurdaydin, C, Diago, M, Gurel, S, Lai, M-Y, Brunetto, M R, Farci, P, Popescu, M, McCloud, P

“…Objective: In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response…”
Get full text

Treatment of chronic hepatitis B by Marcellin, P., Asselah, T., Boyer, N.

“…In the last years, marked progress has been made in the treatment of chronic hepatitis B. The efficacy of lamivudine, the first nucleoside analogue available,…”
Get full text

Gene expression and hepatitis C virus infection by Asselah, T, Bièche, I, Sabbagh, A, Bedossa, P, Moreau, R, Valla, D, Vidaud, M, Marcellin, P

“…Hepatitis C virus (HCV) is a major cause of chronic liver disease, with about 170 million people infected worldwide. Up to 70% of patients will have persistent…”
Get more information

Long-term clearance of hepatitis C virus following interferon [alpha]-2b or peginterferon [alpha]-2b, alone or in combination with ribavirin by Manns, M. P, Pockros, P. J, Norkrans, G, Smith, C. I, Morgan, T. R, Häussinger, D, Shiffman, M. L, Hadziyannis, S. J, Schmidt, W. N, Jacobson, I. M, Bárcena, R, Schiff, E. R, Shaikh, O. S, Bacon, B, Marcellin, P, Deng, W, Esteban-Mur, R, Poynard, T, Pedicone, L. D, Brass, C. A, Albrecht, J. K, Gordon, S. C

“…Summary Sustained virologic response (SVR) is the standard measure for evaluating response to therapy in patients with chronic hepatitis C (CHC). The aim of…”
Get full text

Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4 by Moucari, R, Ripault, M-P, Martinot-Peignoux, M, Voitot, H, Cardoso, A-C, Stern, C, Boyer, N, Maylin, S, Nicolas-Chanoine, M-H, Vidaud, M, Valla, D, Bedossa, P, Marcellin, P

“…Hepatitis C virus (HCV) genotype 4 (HCV-4) is increasing in prevalence in Western countries. However, little is known about the severity of the disease and…”
Get more information

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin by Manns, M. P., Pockros, P. J., Norkrans, G., Smith, C. I., Morgan, T. R., Häussinger, D., Shiffman, M. L., Hadziyannis, S. J., Schmidt, W. N., Jacobson, I. M., Bárcena, R., Schiff, E. R., Shaikh, O. S., Bacon, B., Marcellin, P., Deng, W., Esteban-Mur, R., Poynard, T., Pedicone, L. D., Brass, C. A., Albrecht, J. K., Gordon, S. C.

“…Summary Sustained virologic response (SVR) is the standard measure for evaluating response to therapy in patients with chronic hepatitis C (CHC). The aim of…”
Get full text

HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg‐positive chronic hepatitis B patients by Wong, D., Littlejohn, M., Yuen, L., Jackson, K., Mason, H., Bayliss, J., Rosenberg, G., Gaggar, A., Kitrinos, K., Subramanian, M., Marcellin, P., Buti, M., Janssen, H. L. A., Gane, E., Locarnini, S., Thompson, A., Revill, P. A.

“…Summary Background Hepatitis B e antigen (HBeAg) seroconversion is a treatment endpoint for HBeAg‐positive CHB, and a necessary precursor to HBsAg loss…”
Get full text

Whole-genome deep sequencing of hepatitis B virus in chronic hepatitis B patients reveals single nucleotide variants associated with baseline HBV DNA levels and HBeAg status by Podlaha, O, Revill, P, Bhardwaj, N, Zhuo, L, Kitrinos, K, Gaggar, A, Jiang, Z, Marcellin, P, Locarnini, S, Chan, H.L

Get full text

Whole-genome sequencing of patients achieving hepatitis B virus serum antigen loss following tenofovir disoproxil fumerate (TDF) and/or pegylated-interferon α-2a (PEG) therapy by Kleinstein, S.E, Marcellin, P, Chan, H.L, Shea, P.R, Gaggar, A, Kitrinos, K, Jump, B, Subramanian, G.M, Peterson, J, Goldstein, D.B

Get full text

Evaluation of serum HBV RNA and HBcrAg in chronic hepatitis B patients achieving different serological outcomes on tenofovir disoproxil fumarate (TDF) by Cathcart, A.L, Buti, M, Marcellin, P, Gaggar, A, Delaney, W, Kitrinos, K.M, van Bömmel, F

Get full text

Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study by Semenova, T, Nemoz, B, Thibault, V, Lagathu, G, Duverlie, G, Brochot, E, Trimoulet, P, Payan, C, Vallet, S, Henquell, C, Chevaliez, S, Bouvier-Alias, M, Maylin, S, Roque-Afonso, A-M, Izquierdo, L, Lunel-Fabiani, F, Marcellin, P, Morand, P, Leroy, V, Larrat, S

“…Treatment options for Hepatitis C infection have greatly improved with direct-acting antiviral (DAA) combinations achieving high cure rates. Nevertheless, the…”
Get full text